Pasar al contenido principal

Undiscoveried molecular and cellular mechanisms in paracrine senescence through small extracellular vesicles

RYC2021-032567-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Desarrollar, Atraer y Retener Talento
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDADE DA CORUÑA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Development of New Non-viral Systems for Genetic Modification of Senescent Cells

  • López-Seijas, Junquera
  • Miranda-Balbuena, Diego
  • Iglesias-Fente, Alba
  • Sacristán-Santos, Marta
  • Carballo-Pedrares, Natalia
  • Arufe, M.C.
  • Rey-Rico, Ana
  • Fafián-Labora, J.A.
[Abstract] Senescence is a process characterized by a prolonged irreversible cell-cycle arrest. The accumulation of senescent cells in tissues is related to aging and to the development of age-related diseases. Recently, gene therapy has emerged as a powerful tool for treating age-associated diseases by the transference of specific genes into the target cell population. However, the high sensitivity of senescent cells significantly precludes their genetic modification via classical viral and non-viral systems. Niosomes are self-assembled non-viral nanocarriers that exhibit important advantages due to their elevated cytocompatibility, versatility, and cost-efficiency, arising as a new alternative for genetic modification of senescent cells. In this work, we explore for the first time the use of niosomes for genetic modification of senescent umbilical cord-derived mesenchymal stem cells. We report that niosome composition greatly affected transfection efficiency; those formulations prepared in medium with sucrose and containing cholesterol as helper lipid being the most suitable to transfect senescent cells. Moreover, resulting niosome formulations exhibited a superior transfection efficiency with a markedly less cytotoxicity than the commercial reagent Lipofectamine. These findings highlight the potentiality of niosomes as effective vectors for genetic modification of senescent cells, providing new tools for the prevention and/or treatment of age-related diseases., The work was supported by MICINN (RTI2018-099389-A-100; RYC2018-025617-I; RYC2021-032567-I), Xunta de Galicia (ED431F2021/10; ED481D-2021-020), and Spanish National Health Institute Carlos III (PI20/00497). J.L.-S. acknowledges MICINN (FPU20/06176) for her pre-doctoral fellowship grant. J.F.-L. also gives thanks to the InTalent program from UDC-Inditex for the research grant., Xunta de Galicia; ED431F2021/10, Xunta de Galicia; ED481D-2021-020
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ZenoSWATH DIA proteomics and clustering analysis of the effect of cysteamine at the cellular level in cystinotic fibroblasts

  • Ortea, Ignacio
  • Rodríguez-Martínez, Lorena
  • Carrera, Mónica
  • Fafián-Labora, Juan
  • Arufe, María C.
  • González-Barcia, Miguel
  • Fernández-Ferreiro, Anxo
  • Mateos, Jesús
12 pages, 1 table, 4 figures, Cysteamine, an aminothiol, is the only available treatment for cystinosis, an incurable metabolic recessive disease characterized by detrimental symptoms at the renal, ocular, and muscular levels. Cystinosis is due to mutations in the CTNS gene encoding for the lysosomal symporter cystinosine. Cysteamine treatment only delays the symptoms, presents undesirable side effects and the patients depend on it for life. Thus, it is of paramount importance to find new complementary therapeutic targets for the disease, as well as to understand, at the molecular level, both the beneficial and detrimental effects of cysteamine. Here, we have used ZenoSWATH DIA proteomics and clustering analysis to unravel the differences between cystinotic and non-cystinotic skin fibroblasts, and to study the effect of increasing concentrations of cysteamine. Cystinotic cells present significant differences in proteins related to extracellular matrix structure and detoxification. Only a subset of those proteins is reversed by cysteamine in a dose-dependent manner, partially providing an explanation for its therapeutic benefits. Finally, cysteamine per se alters the levels of a group of lysosomal proteins that are not modulated in basal conditions. Our results will be helpful to understand the benefits, deficiencies, and detrimental effects of the cysteamine treatment., This research was funded by the 2023 Santiago Grisolía Grant (Fundación Mehuer/Real e Ilustre Colegio Oficial de Farmaceúticos de Sevilla), Fundación Mutua Madrileña (XIX Convocatoria de Ayudas a la Investigación en Salud 2022, AP180492022) and Xunta de Galicia-GAIN (IN607A 2023/04). J.M. acknowledges the support of Xunta de Galicia (GAIN) through the Senior Talent Research grant (11_IN858A_2021_1141142). L.R-M was supported by Xunta de Galicia-Galician Innovation Agency (GAIN) through the post-doctoral fellowship “Programa de axudas á etapa posdoutoral” (IN606B-2023/004) and gratefully acknowledges financial support by the Fulbright U.S. Student Program, which is sponsored by the U.S. Department of State and the U.S.-Spain Fulbright Commission. J.A.F-L. was funded by Xunta de Galicia, grant number ED481D-2021-020, Ministerio de Ciencia e Innovación (RYC2021-032567-I), the InTalent program from UDC-Inditex for the research grant and Project PI23/01347, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. M.C.A. has been funded by the project "PI20/00497", funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. J.A.F-L. and M.C.A. are funded by Xunta de Galicia (ED431F 2023/30). Financing for open access position: Fundación Profesor Novoa Santos. M.C. was founded by Spanish AEI/EU-FEDER PID2019-103845RB-C21 project. ISPA's Proteomics Unit has been funded by the Instituto de Salud Carlos III (ISCIII) (project IFCS22/00006) within the framework of the Mechanism for Recovery and Resilience (MRR) of the Next Generation EU funds., Peer reviewed